| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |